Physician profile
Anu Chaudhry
NPI 1295709061
$5,695.07
in general payments reported to CMS, 2019-2025
38 companies · $1,583 in 2025
The $1,583 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $152 · 2021: $460 · 2022: $885 · 2023: $1,201 · 2024: $1,307 · 2025: $1,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,090.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $543.97 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $486.32 | 2020-2025 | Farxiga, Lokelma |
| Amgen INC. | $426.18 | 2021-2025 | Tavneos |
| Novo Nordisk INC | $379.69 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Vifor Pharma, INC. | $372.55 | 2019-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $371.10 | 2022-2025 | Jynarque, Voyxact |
| Ani Pharmaceuticals, INC. | $336.53 | 2022-2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $293.91 | 2021-2025 | |
| Baxter Healthcare | $273.46 | 2023-2025 | Renal - Chronic, Renal - Pd, Hillrom - Carnation Ambulatory Monitor |
| Mallinckrodt Hospital Products INC. | $238.89 | 2020-2025 | Acthar |
| Calliditas Therapeutics US INC. | $181.36 | 2023-2025 | Tarpeyo |
| Ardelyx, INC. | $167.05 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Abbott Laboratories | $154.24 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Daiichi Sankyo INC. | $115.89 | 2020-2023 | Injectafer |
| Lilly USA, LLC | $115.06 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $107.97 | 2022-2025 | Symplicity G3, Minimed 770g |
| Glaxosmithkline, LLC. | $102.16 | 2022-2025 | Benlysta, Jesduvroq, Arexvy |
| Horizon Therapeutics Plc | $98.46 | 2020-2022 | |
| Fresenius USA Marketing, INC. | $97.08 | 2019-2025 | Velphoro, Velphoro |
| Akebia Therapeutics INC | $89.01 | 2024-2025 | Vafseo, Auryxia |
| Dexcom, INC. | $86.83 | 2022-2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $79.36 | 2021-2024 | Gvoke Hypopen |
| Insulet Corporation | $71.34 | 2025 | Omnipod |
| Travere Therapeutics, INC. | $70.90 | 2025 | |
| Exact Sciences Corporation | $61.88 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.26 | 2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.48 | 2024 | Xifaxan |
| Aurinia Pharma U.S., INC. | $42.88 | 2023-2025 | Lupkynis |
| Pfizer INC. | $42.13 | 2019-2023 | |
| Opko Pharmaceuticals, LLC | $30.03 | 2025 | Rayaldee |
| Takeda Pharmaceuticals U.S.A., INC. | $29.13 | 2023-2025 | Gattex |
| Abbvie INC. | $29.03 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.32 | 2025 | Ultomiris |
| Ultragenyx Pharmaceutical INC. | $19.69 | 2022 | |
| Alnylam Pharmaceuticals INC. | $16.83 | 2024 | Onpattro |
| Sanofi-Aventis U.S. LLC | $15.78 | 2022 | |
| Kyowa Kirin, INC. | $15.21 | 2023 | Crysvita |
| Amarin Pharma, INC. | $15.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anu Chaudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.